ACK2-dependent mechanism for activation of the JAK-STAT signaling pathway

Ying Zheng, Hongwei Qin, Stuart J. Frank, Luqin Deng, David W. Litchfield, Ayalew Tefferi, Animesh D Pardanani, Fang Tsyr Lin, Jingzhi Li, Bingdong Sha, Etty N. Benveniste

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

JAK-STAT signaling is involved in the regulation of cell survival, proliferation, and differentiation. JAK tyrosine kinases can be transiently activated by cytokines or growth factors in normal cells, whereas they become constitutively activated as a result of mutations that affect their function in tumors. Specifically, the JAK2V617F mutation is present in the majority of patients with myeloproliferative disorders (MPDs) and is implicated in the pathogenesis of these diseases. In the present study, we report that the kinase CK2 is a novel interaction partner of JAKs and is essential for JAK-STAT activation.We demonstrate that cytokine-induced activation of JAKs and STATs and the expression of suppressor of cytokine signaling 3 (SOCS-3), a downstream target, are inhibited by CK2 small interfering RNAs or pharmacologic inhibitors. Endogenous CK2 is associated with JAK2 and JAK1 and phosphorylates JAK2 in vitro. To extend these findings, we demonstrate that CK2 interacts with JAK2V617F and that CK2 inhibitors suppress JAK2V617F autophosphorylation and downstream signaling in HEL92.1.7 cells (HEL) and primary cells from polycythemia vera (PV) patients. Furthermore, CK2 inhibitors potently induce apoptosis of HEL cells and PV cells. Our data provide evidence for novel cross-talk between CK2 and JAK-STAT signaling, with implications for therapeutic intervention in JAK2V617F-positive MPDs.

Original languageEnglish (US)
Pages (from-to)156-166
Number of pages11
JournalBlood
Volume118
Issue number1
DOIs
StatePublished - Jul 7 2011

Fingerprint

Chemical activation
Polycythemia Vera
Cytokines
Myeloproliferative Disorders
Cell proliferation
Protein-Tyrosine Kinases
Small Interfering RNA
Janus Kinases
Tumors
Intercellular Signaling Peptides and Proteins
Mutation
Phosphotransferases
Apoptosis
Cell Differentiation
Cell Survival
Cell Proliferation
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Zheng, Y., Qin, H., Frank, S. J., Deng, L., Litchfield, D. W., Tefferi, A., ... Benveniste, E. N. (2011). ACK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood, 118(1), 156-166. https://doi.org/10.1182/blood-2010-01-266320

ACK2-dependent mechanism for activation of the JAK-STAT signaling pathway. / Zheng, Ying; Qin, Hongwei; Frank, Stuart J.; Deng, Luqin; Litchfield, David W.; Tefferi, Ayalew; Pardanani, Animesh D; Lin, Fang Tsyr; Li, Jingzhi; Sha, Bingdong; Benveniste, Etty N.

In: Blood, Vol. 118, No. 1, 07.07.2011, p. 156-166.

Research output: Contribution to journalArticle

Zheng, Y, Qin, H, Frank, SJ, Deng, L, Litchfield, DW, Tefferi, A, Pardanani, AD, Lin, FT, Li, J, Sha, B & Benveniste, EN 2011, 'ACK2-dependent mechanism for activation of the JAK-STAT signaling pathway', Blood, vol. 118, no. 1, pp. 156-166. https://doi.org/10.1182/blood-2010-01-266320
Zheng, Ying ; Qin, Hongwei ; Frank, Stuart J. ; Deng, Luqin ; Litchfield, David W. ; Tefferi, Ayalew ; Pardanani, Animesh D ; Lin, Fang Tsyr ; Li, Jingzhi ; Sha, Bingdong ; Benveniste, Etty N. / ACK2-dependent mechanism for activation of the JAK-STAT signaling pathway. In: Blood. 2011 ; Vol. 118, No. 1. pp. 156-166.
@article{9392baeb04894b419855ecfee1fbe8a2,
title = "ACK2-dependent mechanism for activation of the JAK-STAT signaling pathway",
abstract = "JAK-STAT signaling is involved in the regulation of cell survival, proliferation, and differentiation. JAK tyrosine kinases can be transiently activated by cytokines or growth factors in normal cells, whereas they become constitutively activated as a result of mutations that affect their function in tumors. Specifically, the JAK2V617F mutation is present in the majority of patients with myeloproliferative disorders (MPDs) and is implicated in the pathogenesis of these diseases. In the present study, we report that the kinase CK2 is a novel interaction partner of JAKs and is essential for JAK-STAT activation.We demonstrate that cytokine-induced activation of JAKs and STATs and the expression of suppressor of cytokine signaling 3 (SOCS-3), a downstream target, are inhibited by CK2 small interfering RNAs or pharmacologic inhibitors. Endogenous CK2 is associated with JAK2 and JAK1 and phosphorylates JAK2 in vitro. To extend these findings, we demonstrate that CK2 interacts with JAK2V617F and that CK2 inhibitors suppress JAK2V617F autophosphorylation and downstream signaling in HEL92.1.7 cells (HEL) and primary cells from polycythemia vera (PV) patients. Furthermore, CK2 inhibitors potently induce apoptosis of HEL cells and PV cells. Our data provide evidence for novel cross-talk between CK2 and JAK-STAT signaling, with implications for therapeutic intervention in JAK2V617F-positive MPDs.",
author = "Ying Zheng and Hongwei Qin and Frank, {Stuart J.} and Luqin Deng and Litchfield, {David W.} and Ayalew Tefferi and Pardanani, {Animesh D} and Lin, {Fang Tsyr} and Jingzhi Li and Bingdong Sha and Benveniste, {Etty N.}",
year = "2011",
month = "7",
day = "7",
doi = "10.1182/blood-2010-01-266320",
language = "English (US)",
volume = "118",
pages = "156--166",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - ACK2-dependent mechanism for activation of the JAK-STAT signaling pathway

AU - Zheng, Ying

AU - Qin, Hongwei

AU - Frank, Stuart J.

AU - Deng, Luqin

AU - Litchfield, David W.

AU - Tefferi, Ayalew

AU - Pardanani, Animesh D

AU - Lin, Fang Tsyr

AU - Li, Jingzhi

AU - Sha, Bingdong

AU - Benveniste, Etty N.

PY - 2011/7/7

Y1 - 2011/7/7

N2 - JAK-STAT signaling is involved in the regulation of cell survival, proliferation, and differentiation. JAK tyrosine kinases can be transiently activated by cytokines or growth factors in normal cells, whereas they become constitutively activated as a result of mutations that affect their function in tumors. Specifically, the JAK2V617F mutation is present in the majority of patients with myeloproliferative disorders (MPDs) and is implicated in the pathogenesis of these diseases. In the present study, we report that the kinase CK2 is a novel interaction partner of JAKs and is essential for JAK-STAT activation.We demonstrate that cytokine-induced activation of JAKs and STATs and the expression of suppressor of cytokine signaling 3 (SOCS-3), a downstream target, are inhibited by CK2 small interfering RNAs or pharmacologic inhibitors. Endogenous CK2 is associated with JAK2 and JAK1 and phosphorylates JAK2 in vitro. To extend these findings, we demonstrate that CK2 interacts with JAK2V617F and that CK2 inhibitors suppress JAK2V617F autophosphorylation and downstream signaling in HEL92.1.7 cells (HEL) and primary cells from polycythemia vera (PV) patients. Furthermore, CK2 inhibitors potently induce apoptosis of HEL cells and PV cells. Our data provide evidence for novel cross-talk between CK2 and JAK-STAT signaling, with implications for therapeutic intervention in JAK2V617F-positive MPDs.

AB - JAK-STAT signaling is involved in the regulation of cell survival, proliferation, and differentiation. JAK tyrosine kinases can be transiently activated by cytokines or growth factors in normal cells, whereas they become constitutively activated as a result of mutations that affect their function in tumors. Specifically, the JAK2V617F mutation is present in the majority of patients with myeloproliferative disorders (MPDs) and is implicated in the pathogenesis of these diseases. In the present study, we report that the kinase CK2 is a novel interaction partner of JAKs and is essential for JAK-STAT activation.We demonstrate that cytokine-induced activation of JAKs and STATs and the expression of suppressor of cytokine signaling 3 (SOCS-3), a downstream target, are inhibited by CK2 small interfering RNAs or pharmacologic inhibitors. Endogenous CK2 is associated with JAK2 and JAK1 and phosphorylates JAK2 in vitro. To extend these findings, we demonstrate that CK2 interacts with JAK2V617F and that CK2 inhibitors suppress JAK2V617F autophosphorylation and downstream signaling in HEL92.1.7 cells (HEL) and primary cells from polycythemia vera (PV) patients. Furthermore, CK2 inhibitors potently induce apoptosis of HEL cells and PV cells. Our data provide evidence for novel cross-talk between CK2 and JAK-STAT signaling, with implications for therapeutic intervention in JAK2V617F-positive MPDs.

UR - http://www.scopus.com/inward/record.url?scp=79960119979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960119979&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-01-266320

DO - 10.1182/blood-2010-01-266320

M3 - Article

C2 - 21527517

AN - SCOPUS:79960119979

VL - 118

SP - 156

EP - 166

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -